Eli Lilly’s Employer Connect: A New Prescription for Obesity Care Access?
Eli Lilly is tackling a critical barrier to widespread obesity treatment: access. The pharmaceutical giant has launched “Employer Connect,” a platform designed to bridge the gap between patients, employers, and independent program administrators, aiming to make medications like Zepbound more readily available to U.S. Workers.
The Challenge of Affordability and Coverage
Despite growing medical demand, a significant hurdle remains: cost and inconsistent insurance coverage. Lilly estimates that roughly half of individuals with commercial insurance face difficulties initiating or continuing obesity medication treatment. This lack of access isn’t just a patient issue; it’s a business impediment for Lilly, limiting the potential market for its drugs.
How Employer Connect Works
The Employer Connect platform facilitates direct connections between employers and over 15 independent program administrators. These administrators can then develop tailored, transparent solutions for employees seeking obesity care. A key feature is the offering of Zepbound (tirzepatide) at a list price of $449 per month for all dosages, without traditional rebates. This aims to provide employers with greater cost predictability.
Employers can choose from administrators offering basic services like enrollment and claims processing, or more comprehensive programs including telemedicine, nutritional guidance, and lifestyle support. Currently, approximately 20% of companies with over 200 employees cover GLP-1 medications for weight loss, rising to 43% for larger employers (5,000+ employees).
A Shift in Industry Approach
Experts view Employer Connect as an incremental but significant step. Previously, manufacturers and pharmacy benefit managers often opposed external discount programs. Now, GLP-1 providers are increasingly collaborating with these models to expand access. This represents a notable change in strategy.
Lilly’s Financial Momentum and Future Pipeline
Lilly’s financial performance is currently bolstered by its incretin products. In 2025, the company reported $65.2 billion in revenue (+45%) and earnings per share of $24.21 (+86%). Mounjaro and Zepbound drove much of this growth, increasing by 99% and 175% respectively.
However, this success also creates a concentration risk. Currently, these two GLP-1 products account for 56% of Lilly’s total revenue. The company is actively diversifying its pipeline with oral GLP-1 options like orforglipron, which is awaiting FDA approval, and retatrutide, currently in Phase 3 trials.
Looking Ahead: Orforglipron and Beyond
The FDA decision on orforglipron, expected in the second quarter of 2026, is a key catalyst for Lilly. International launches are planned for 2027. Phase 3 data for retatrutide will also be closely watched, as Lilly seeks to demonstrate its ability to sustain growth beyond its current GLP-1 offerings.
Lilly’s stock has experienced recent downward pressure (-4.24% in the last week). Investors will be looking for positive developments regarding orforglipron and retatrutide to reaffirm confidence in the company’s long-term growth prospects.
Frequently Asked Questions
Q: What is Zepbound?
A: Zepbound (tirzepatide) is a medication developed by Eli Lilly for weight management.
Q: What does Employer Connect aim to achieve?
A: Employer Connect seeks to improve access to obesity medications like Zepbound by connecting employers with program administrators offering affordable and comprehensive care solutions.
Q: How does the $449 price point for Zepbound work?
A: The $449 price is a list price offered through the platform, and importantly, excludes traditional rebates, providing employers with greater cost transparency.
Q: What is orforglipron?
A: Orforglipron is an oral GLP-1 medication in development by Eli Lilly, awaiting FDA approval.
What are your thoughts on Eli Lilly’s new platform? Share your comments below!
